Amyloid-Beta Peptide
ABP
Description
"Amyloid-Beta Peptide" test measures levels of amyloid-beta proteins in cerebrospinal fluid or blood to assess risk for Alzheimer’s disease. Abnormal levels may indicate amyloid plaque buildup in the brain, often linked to cognitive decline. Doctors order this test when symptoms like memory loss or confusion raise concern. Results help detect early changes associated with Alzheimer’s and guide further evaluation or treatment. Ongoing monitoring supports diagnosis, tracks progression, and helps personalize care for patients facing neurocognitive symptoms.
Category
Proteins
Procedure
Invasive
Sample Type
Blood – Plasma
Units
Nanograms Per Liter
Procedure Category
Blood Draw
Test Group
Chronic Illness Group
Test Group Description
Chronic Illness Group: This group encompasses a range of tests specifically tailored to assess markers associated with chronic health conditions, providing comprehensive insights into the management and monitoring of chronic illnesses.
Optimal Range
For All Individuals (> 50 years):
Conventional Unit: Not Available
SI Unit: Not Available
Normal Range
For All Individuals (> 50 years):
Conventional Unit: > 620.00 ng/L
SI Unit: Not Frequently Used
Results That Differ From The Norm (Direct and Indirect Causes)
Abnormal results may indicate:
Alzheimer's disease (Neurodegenerative disorder characterized by cognitive decline and memory loss)
Frontotemporal dementia (Brain disorder leading to changes in behavior, personality, and language due to frontal and temporal lobe degeneration)
Lewy body dementia (Progressive dementia with abnormal protein deposits known as Lewy bodies in the brain)
Mild cogn...
Key Reasons For Testing
Diagnosis of Alzheimer’s Disease: Measures amyloid-beta levels to aid in diagnosing Alzheimer’s.
Prediction of Disease Progression: Evaluates how Alzheimer’s may advance based on amyloid-beta levels.
Assessment of Treatment Response: Tracks changes in amyloid-beta to evaluate therapy effectiveness.
Screening for Alzheimer’s Risk: Identifies individuals at higher risk, especially with a family history.
Health Status Conditions It May Be Used To Assess
Currently, this test is not directly associated with any conditions listed on the Health Status page. However, it may be included as part of a broader set of tests linked to specific health conditions.
Some Prominent Medical Labs That May Offer This Test
Please note that this particular test has not been associated with any of the listed prominent medical labs. We recommend enquiring with your private physician or nearest hospital to determine where this specific test can be performed.
References
Important Note
Any medical procedure yielding results outside the norm may be directly or indirectly linked to the conditions outlined on this page. Various factors, including genetics, medication and supplement usage, recent illnesses, pregnancy, pre-test eating, smoking, and stress, can impact the test's outcome. Additionally, factors like false positives, false negatives, inaccurate analyses, and others can influence results.
Reference ranges, which help healthcare professionals interpret medical tests, may vary depending on age, gender, and other factors. They may also differ between laboratories due to variations in instruments and methods used. Optimal ranges are designed for preventive purposes, aiming to identify trends and potential risks early, while normal ranges reflect conventional laboratory values indicating no current disease or pathology. Your healthcare practitioner may have specific reasons for testing that deviate from the usual or may interpret results differently based on individual circumstances. Proper interpretation typically involves considering clinical findings and other diagnostic tests. Hence, it is crucial to provide your healthcare professionals with a comprehensive medical history, consult with them for result interpretation, and follow their guidance for potential re-testing or additional diagnostics.
Disclaimer
This content is provided solely for informative and educational purposes. It is not intended as a substitute for medical advice or treatment from a personal physician. Regarding the interpretation of their medical test results and/or specific health questions, it is recommended that all readers and viewers consult their physicians or other qualified health professionals. The publisher is not responsible for any adverse health effects that may result from reading or following the information in this educational content. Before beginning any nutrition, supplement, or lifestyle program, all viewers, especially those taking prescription or over-the-counter medications, should consult their physician or health care practitioner.
Please note that while prominent lab names are included in this content, we cannot guarantee that these labs offer all the tests mentioned. For confirmation, individuals should contact the labs directly or consult their medical practitioners. The information provided reflects general knowledge at the time of publication and may not include recent updates or emerging research. Readers should verify details with qualified professionals to ensure the most up-to-date and accurate guidance.
[1] Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science. 1992;256(5054):184-185.
[2] Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev. 2001;81(2):741-766.
[3] Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012;367(9):795-804.
[4] Jack CR Jr, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12(2):207-216.
[5] Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria. Lancet Neurol. 2007;6(8):734-746.
[6] Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid amyloid-β42 in humans. Ann Neurol. 2006;59(3):512-519.
[7] Hansson O, Zetterberg H, Buchhave P, et al. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006;5(3):228-234.
[8] Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6(3):131-144.
[9] Villemagne VL, Pike KE, Darby D, et al. Aβ deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. Neurobiol Aging. 2008;29(9):1231-1238.
[10] Jansen WJ, Ossenkoppele R, Knol DL, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA. 2015;313(19):1924-1938.
[11] Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging and the Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):280-292.